February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?
- Author
- Health Advance
- Published
- Thu 03 Feb 2022
- Episode Link
- https://www.gynecologiconcology-online.net/pb-assets/Health%20Advance/journals/ygyno/podcasts/Feb_0222_GynOnc_Podcast_Huh_Swisher_Ledermann.mp3
Hosted by:
Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology
Featuring:
Elizabeth Swisher, MD, UW Medicine
Jonathan A Ledermann, MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer Institute
Editor’s Choice Paper: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Editorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?
